Project Details
Description
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) Blineage leukemia or lymphoma
| Status | Finished |
|---|---|
| Effective start/end date | 12/19/14 → 12/30/20 |
Funding
- GT BIOPHARMA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.